Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Manufacturers Will Cut Into India's Vaccine Exports Unless Indian Firms Can Find New Approach - World Vaccine Congress Asia

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - China will overtake India as the world's largest producer of vaccines in the coming years unless Indian companies manage properly their current niche in export markets, speakers said at the World Vaccine Congress Asia 2011 held June 20-24 in Singapore

You may also be interested in...



Pharma’s Aim: Tap Innovation In Emerging Markets To Fix Woes At Home (Part 1 of 2)

Pharma must learn how to apply the best of its experiences in emerging markets to its traditional business, or, experts warn, invigorated competition from more nimble, faster-growing local players that have enjoyed success on their own turf will become a global threat.

Pharma’s Aim: Tap Innovation In Emerging Markets To Fix Woes At Home

Pharma must learn how to apply the best of its experiences in emerging markets to its traditional business, or, experts warn, invigorated competition from more nimble, faster-growing local players who have enjoyed success on their own turf will become a global threat.

China's Simcere Reports Slow Q1 Results, But Sales Force Reorganization Could Help Attract New Pharma Partners

SHANGHAI - Simcere Pharmaceutical Group, one of the first Chinese domestic pharmaceutical companies to list in the U.S., reported a slow first quarter result due to slower than expected sales of lead product line first-to-market edavarone injection branded Bicun and Yidasheng.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel